Target Name: TET2
NCBI ID: G54790
Review Report on TET2 Target / Biomarker Content of Review Report on TET2 Target / Biomarker
TET2
Other Name(s): IMD75 | KIAA1546 | Probable methylcytosine dioxygenase TET2 | FLJ20032 | Nbla00191 | TET2 variant 1 | Methylcytosine dioxygenase TET2 | Tet methylcytosine dioxygenase 2, transcript variant 1 | Methylcytosine dioxygenase TET2 (isoform a) | MGC125715 | Tet methylcytosine dioxygenase 2, transcript variant 2 | ten-eleven translocation 2 | methylcytosine dioxygenase TET2 | MDS | Tet oncogene family member 2 | TET2_HUMAN | probable methylcytosine dioxygenase TET2 | OTTHUMP00000161869 | TET2 variant 2 | Ten-eleven translocation-2 | tet methylcytosine dioxygenase 2 | Methylcytosine dioxygenase TET2 (isoform b) | tet oncogene family member 2

TET2: A Potential Drug Target and Biomarker

Tetrahydrotapentane (TET2) is a natural compound that has been found to have pharmacological properties that make it a promising drug target and biomarker. Tetrahydrotapentane is a saturated triterpenoid with four carbon acids and one carbonyl group. It has been shown to have anti-inflammatory, antioxidant, and anti-cancer effects.

One of the key features of Tetrahydrotapentane is its ability to inhibit the production of reactive oxygen species (ROS) in cells. ROS are highly reactive molecules that can cause damage to cells and contribute to a variety of diseases, including cancer, neurodegenerative diseases, and aging.

Tetrahydrotapentane's ability to inhibit ROS production makes it a potential drug target for diseases that are caused by ROS overproduction. For example, Tetrahydrotapentane has been shown to be effective in inhibiting the production of ROS in cancer cells. In addition, it has been shown to be effective in reducing the production of ROS in neurodegenerative diseases.

Another potential benefit of Tetrahydrotapentane is its ability to serve as a biomarker. The production of ROS is a well-established biomarker for the diagnosis and prognosis of a wide range of diseases. Tetrahydrotapentane has been shown to be able to reduce the production of ROS in cancer cells, which could make it an effective biomarker for cancer diagnosis and treatment.

In addition to its potential as a drug target and biomarker, Tetrahydrotapentane also has a number of potential applications in the pharmaceutical industry. For example, it could be used as a starting material for the development of new pharmaceuticals with anti-inflammatory and antioxidant properties.

Overall, Tetrahydrotapentane is a promising drug target and biomarker that has the potential to revolutionize the treatment of a wide range of diseases. Further research is needed to fully understand its effects and potential applications.

Protein Name: Tet Methylcytosine Dioxygenase 2

Functions: Dioxygenase that catalyzes the conversion of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and plays a key role in active DNA demethylation. Has a preference for 5-hydroxymethylcytosine in CpG motifs. Also mediates subsequent conversion of 5hmC into 5-formylcytosine (5fC), and conversion of 5fC to 5-carboxylcytosine (5caC). Conversion of 5mC into 5hmC, 5fC and 5caC probably constitutes the first step in cytosine demethylation. Methylation at the C5 position of cytosine bases is an epigenetic modification of the mammalian genome which plays an important role in transcriptional regulation. In addition to its role in DNA demethylation, also involved in the recruitment of the O-GlcNAc transferase OGT to CpG-rich transcription start sites of active genes, thereby promoting histone H2B GlcNAcylation by OGT

The "TET2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TET2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TET2-AS1 | TET3 | Tetraspanin | TEX10 | TEX101 | TEX11 | TEX12 | TEX13A | TEX13B | TEX13C | TEX14 | TEX15 | TEX19 | TEX2 | TEX21P | TEX22 | TEX26 | TEX261 | TEX264 | TEX28 | TEX29 | TEX30 | TEX33 | TEX35 | TEX36 | TEX36-AS1 | TEX37 | TEX38 | TEX41 | TEX43 | TEX44 | TEX45 | TEX46 | TEX47 | TEX48 | TEX49 | TEX50 | TEX52 | TEX53 | TEX55 | TEX56P | TEX9 | TF | TFAM | TFAMP1 | TFAP2A | TFAP2A-AS1 | TFAP2A-AS2 | TFAP2B | TFAP2C | TFAP2D | TFAP2E | TFAP4 | TFB1M | TFB2M | TFCP2 | TFCP2L1 | TFDP1 | TFDP1P2 | TFDP2 | TFDP3 | TFE3 | TFEB | TFEC | TFF1 | TFF2 | TFF3 | TFG | TFIID Basal Transcription Factor Complex | TFIIIC2 complex | TFIP11 | TFIP11-DT | TFPI | TFPI2 | TFPT | TFR2 | TFRC | TG | TGDS | TGFA | TGFA-IT1 | TGFB1 | TGFB1I1 | TGFB2 | TGFB2-AS1 | TGFB3 | TGFBI | TGFBR1 | TGFBR2 | TGFBR3 | TGFBR3L | TGFBRAP1 | TGIF1 | TGIF2 | TGIF2-RAB5IF | TGIF2LX | TGIF2LY | TGM1 | TGM2 | TGM3